Prognosis of patients with fulminant myocarditis managed by peripheral venoarterial extracorporeal membranous oxygenation support: a retrospective single-center study

Table 1 Baseline characteristics of patients with fulminant myocarditis with extracorporeal membranous oxygenation (ECMO) support

	Survivors ( n = 13)	Non-survivors ( n = 9)	P value
Age, years	36.5 ± 14.7	60.2 ± 14.9	0.001
Male sex	6 (46%)	4 (44%)	0.64
Systolic BP, mm Hg	84.5 ± 21.7	81.4 ± 27.3	0.78
Heart rate, bpm	110.0 ± 33.3	92.0 ± 26.1	0.22
Presence of pulseless VT or Vf	9 (69%)	6 (67%)	0.90
LVDd, mm	46.0 ± 7.7	44.0 ± 5.4	0.62
LVDs, mm	40.7 ± 7.3	36.4 ± 4.2	0.25
LVEF, %	22.9 ± 8.5	23.6 ± 12.6	0.88
Laboratory data on admission
WBC (/μL)	10,213.9 ± 5,431.6	11,937.8 ± 9,399.0	0.59
GOT (IU/L)	768.6 ± 864.1	1,599.8 ± 2,759.7	0.40
GPT (IU/L)	540.6 ± 726.9	1,044.2 ± 1,882.0	0.46
LDH (IU/L)	2,187.9 ± 2,198.0	2,815.1 ± 4,245.1	0.65
Total-Bil (mg/dL)	0.72 ± 0.29	0.85 ± 0.49	0.46
Direct-Bil (mg/dL)	0.28 ± 0.11	0.37 ± 0.31	0.36
BUN (mg/dL)	26.7 ± 12.4	38.9 ± 29.0	0.26
Creatinine (mg/dL)	1.47 ± 0.76	1.48 ± 0.98	0.99
Max. CK (IU/L)	3,090.2 ± 4,416.1	3,148.0 ± 4,456.2	0.98
Max. CK-MB (IU/L)	154.9 ± 279.8	113.2 ± 70.1	0.67

Data are presented as the mean ± standard deviation or as the number of patients (%).
BP blood pressure, VT ventricular tachycardia, Vf ventricular fibrillation, LVDd left ventricular end-diastolic dimension, LVDs left ventricular end-systolic dimension, LVEF left ventricular ejection fraction, WBC white blood cell, GOT glutamic oxaloacetic transaminase, GPT glutamic pyruvic transaminase, LDH lactate dehydrogenase, Bil bilirubin, BUN blood urea nitrogen, Max. maximum, CK creatine kinase.